Literature DB >> 23671530

Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits.

Chen Zhao1, Du Geon Moon, Jong Kwan Park.   

Abstract

OBJECTIVE: The association between testosterone replacement therapy and cardiovascular risk remains controversial. Blood viscosity is a known individual risk factor for cardiovascular disease mortality. The objective of the present study was to investigate the effects of the long-acting injectable testosterone undecanoate (TU) on risk factors of cardiovascular disease.
METHODS: In total, 24 male New Zealand white rabbits (2.5 kg) were randomly divided into 3 groups of 8. Group 1 was used as control. Group 2 was castrated bilaterally and Group 3 was administrated with 6 mg/kg of TU at day 1 and 6 weeks after castration. Whole blood viscosity, total plasma testosterone, hemoglobin (Hb), hematocrit (Hct), fibrinogen (FBN), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were measured at baseline, 6 weeks and 18 weeks.
RESULTS: In the control group, whole blood viscosity and FBN were significantly increased at 6 and 18 weeks. Castration significantly increased the levels of TC, TG, HDL-C and LDL-C, but decreased Hct and Hb. In the TU injection group, whole blood viscosity was markedly decreased in all share rates, whereas the FBN level was increased. Hb and Hct showed a tendency for higher concentration at 6 weeks.
CONCLUSIONS: Long-acting injectable TU provides another reliable treatment option for testosterone replacement therapy. Moreover, the patients may receive additional beneficial effect in lowered whole blood viscosity.

Entities:  

Year:  2013        PMID: 23671530      PMCID: PMC3650759          DOI: 10.5489/cuaj.507

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  32 in total

1.  Polycythaemia as a complication of transdermal testosterone therapy.

Authors:  J F Viallard; G Marit; P Mercié; B Leng; J Reiffers; J L Pellegrin
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.

Authors:  H M Behre; K Abshagen; M Oettel; D Hübler; E Nieschlag
Journal:  Eur J Endocrinol       Date:  1999-05       Impact factor: 6.664

Review 3.  Age-related changes in testosterone and the role of replacement therapy in older men.

Authors:  Carolyn A Allan; Robert I McLachlan
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

4.  An automated tube-type blood viscometer: validation studies.

Authors:  T Alexy; R B Wenby; E Pais; L J Goldstein; W Hogenauer; H J Meiselman
Journal:  Biorheology       Date:  2005       Impact factor: 1.875

5.  Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin.

Authors:  J Gyllenborg; S L Rasmussen; K Borch-Johnsen; B L Heitmann; N E Skakkebaek; A Juul
Journal:  Metabolism       Date:  2001-08       Impact factor: 8.694

6.  The erythropoietic-stimulating effects of androgens.

Authors:  W Fried; C W Gurney
Journal:  Ann N Y Acad Sci       Date:  1968-03-29       Impact factor: 5.691

7.  Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.

Authors:  M Schubert; T Minnemann; D Hübler; D Rouskova; A Christoph; M Oettel; M Ernst; U Mellinger; W Krone; F Jockenhövel
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

Review 8.  Regulation of hepatic lipase and serum lipoproteins by sex steroids.

Authors:  M J Tikkanen; E A Nikkilä
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

9.  Reference limits of plasma fibrinogen.

Authors:  P Tarallo; J Henny; R Gueguen; G Siest
Journal:  Eur J Clin Chem Clin Biochem       Date:  1992-11

Review 10.  Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature.

Authors:  Kathleen Stergiopoulos; Joseph J Brennan; Robin Mathews; John F Setaro; Smadar Kort
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  4 in total

Review 1.  Erythrocytosis Following Testosterone Therapy.

Authors:  Samuel J Ohlander; Bibin Varghese; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-05-16

2.  The effects of short-term and long-term testosterone supplementation on blood viscosity and erythrocyte deformability in healthy adult mice.

Authors:  Wen Guo; Eric Bachman; Johannes Vogel; Michelle Li; Liming Peng; Karol Pencina; Carlo Serra; Nicolae L Sandor; Ravi Jasuja; Monty Montano; Shehzad Basaria; Max Gassmann; Shalender Bhasin
Journal:  Endocrinology       Date:  2015-03-16       Impact factor: 4.736

Review 3.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

4.  Clinical Significance of Low Blood Testosterone Concentration in Men as a Cardiovascular Risk Factor From the Perspective of Blood Rheology.

Authors:  Takashi Hitsumoto
Journal:  Cardiol Res       Date:  2019-04-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.